Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN1910 · 1 trial · 1 indication
The safety and tolerability of ALXN1910 was assessed.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Participants will receive a single dose of 5 mg of ALXN1910 IV or Placebo IV. |
| Cohort 2 | EXPERIMENTAL | Participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC. |
| Cohort 3 | EXPERIMENTAL | Participant will receive a single dose of 15 mg of ALXN1910 IV or Placebo IV. |
| Cohort 4 | EXPERIMENTAL | Japanese participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC. |
| Cohort 5 | EXPERIMENTAL | Participants will receive a single dose of 45 mg of ALXN1910 SC or Placebo SC. |
| Cohort 6 | EXPERIMENTAL | Participants will receive a single dose of 135 mg of ALXN1910 SC or Placebo SC. |
| Name | Type | Description |
|---|---|---|
| ALXN1910 | DRUG | Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort. |
| Placebo | DRUG | Participants will receive Placebo IV or Placebo SC according to their assigned cohort. |
Inclusion Criteria: * Healthy participants * Participants of Japanese descent are defined as: First generation (born to 2 Japanese parents and 4 Japanese grandparents). * Participants of Japanese descent must be between 20 and 55 years of age. Exclusion Criteria: * Current or recurrent disease * ...
ALXN1910 is an investigational small molecule drug being developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial in healthy adult participants in the United Kingdom. The specific disease or condition it is intended to treat has not been disclosed.
ALXN1910 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating this small molecule candidate.
ALXN1910 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this candidate.
ALXN1910 has been evaluated in one completed Phase 1 trial, NCT05307978, titled a Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants. The trial enrolled 48 healthy volunteers in the United Kingdom and used a randomized, double-blind, controlled design.
The Phase 1 trial of ALXN1910, NCT05307978, enrolled 48 participants. It was a randomized, double-blind, controlled study conducted in healthy volunteers aged 18 years and older in the United Kingdom. The trial has been completed.